title: A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
abstract: The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.
authors.affiliation: aDivision of Cardiology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Naples bClinic of Cardiovascular Diseases, IRCCS San Martino IST, Genoa cDepartment of Medical Sciences 'Mario Aresu', University of Cagliari, Cagliari dInstitute of Cardiology, Center of Excellence on Aging, 'G. d'Annunzio' University, Chieti eCardiology Unit, University Hospital of Ferrara, Ferrara fDepartment of General Surgery and Medical-Surgery Specialties, University of Catania, Catania gChair and Division of Cardiology, University of Palermo, Palermo hDepartment of Clinical and Biological Sciences, University of Turin, Turin iU.O.C. Magnetic Resonance Imaging, Fondazione G. Monasterio C.N.R., Pisa jDepartment of Translational Medical Sciences, Federico II University, Naples kU.O.C. Cardiology Intensive Unit, A.O.U. Policlinico 'G. Martino', University of Messina, Messina, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Maurea
authors.forename: Paolo
authors.initials: P
authors.lastname: Spallarossa
authors.forename: Christian
authors.initials: C
authors.lastname: Cadeddu
authors.forename: Rosalinda
authors.initials: R
authors.lastname: Madonna
authors.forename: Donato
authors.initials: D
authors.lastname: Mele
authors.forename: Ines
authors.initials: I
authors.lastname: Monte
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Novo
authors.forename: Pasquale
authors.initials: P
authors.lastname: Pagliaro
authors.forename: Alessia
authors.initials: A
authors.lastname: Pepe
authors.forename: Carlo G
authors.initials: CG
authors.lastname: Tocchetti
authors.forename: Concetta
authors.initials: C
authors.lastname: Zito
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mercuro
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D066126:Cardiotoxicity / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D019468:Disease Management; D006801:Humans; D007558:Italy; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012955:Societies, Medical
chemical_list: D020533:Angiogenesis Inhibitors